Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
RaQualia Pharma said on December 12 that its board has approved an expansion of its capital and business alliance with South Korea’s HK inno.N, including a plan to license the Japanese rights to its gastric acid reducer tegoprazan. Under the…
To read the full story
Related Article
- RaQualia Partner Files US NDA for Tegoprazan
January 14, 2026
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…